Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 293

1.

Salvage brachytherapy for recurrent prostate cancer after definitive radiation therapy: A comparison of low-dose-rate and high-dose-rate brachytherapy and the importance of prostate-specific antigen doubling time.

Kollmeier MA, McBride S, Taggar A, Anderson E, Lin M, Pei X, Weiji S, Voros L, Cohen G, Yamada Y, Zelefsky MJ.

Brachytherapy. 2017 Aug 21. pii: S1538-4721(17)30416-6. doi: 10.1016/j.brachy.2017.07.013. [Epub ahead of print]

PMID:
28838648
2.

Dosimetric comparison of rectal-sparing capabilities of rectal balloon vs injectable spacer gel in stereotactic body radiation therapy for prostate cancer: lessons learned from prospective trials.

Jones RT, Hassan Rezaeian N, Desai NB, Lotan Y, Jia X, Hannan R, Kim DWN, Hornberger B, Dubas J, Laine AM, Zelefsky MJ, Timmerman RD, Folkert MR.

Med Dosim. 2017 Jul 31. pii: S0958-3947(17)30067-5. doi: 10.1016/j.meddos.2017.07.002. [Epub ahead of print]

PMID:
28774760
3.

Unification of favourable intermediate-, unfavourable intermediate-, and very high-risk stratification criteria for prostate cancer.

Zumsteg ZS, Zelefsky MJ, Woo KM, Spratt DE, Kollmeier MA, McBride S, Pei X, Sandler HM, Zhang Z.

BJU Int. 2017 Nov;120(5B):E87-E95. doi: 10.1111/bju.13903. Epub 2017 Jun 3.

PMID:
28464446
4.

Real-time intraoperative evaluation of implant quality and dose correction during prostate brachytherapy consistently improves target coverage using a novel image fusion and optimization program.

Zelefsky MJ, Cohen GN, Taggar AS, Kollmeier M, McBride S, Mageras G, Zaider M.

Pract Radiat Oncol. 2017 Sep - Oct;7(5):319-324. doi: 10.1016/j.prro.2017.01.009. Epub 2017 Jan 20.

PMID:
28377139
5.

American Brachytherapy Society Task Group Report: Use of androgen deprivation therapy with prostate brachytherapy-A systematic literature review.

Keyes M, Merrick G, Frank SJ, Grimm P, Zelefsky MJ.

Brachytherapy. 2017 Mar - Apr;16(2):245-265. doi: 10.1016/j.brachy.2016.11.017. Epub 2017 Jan 16. Review.

PMID:
28110898
6.

Second malignancy risk in prostate cancer and radiotherapy.

Charas T, Taggar A, Zelefsky MJ.

Future Oncol. 2017 Feb;13(5):385-389. doi: 10.2217/fon-2016-0503. Epub 2017 Jan 17. No abstract available.

PMID:
28092982
7.

The impact of histology and delivered dose on local control of spinal metastases treated with stereotactic radiosurgery.

Yamada Y, Katsoulakis E, Laufer I, Lovelock M, Barzilai O, McLaughlin LA, Zhang Z, Schmitt AM, Higginson DS, Lis E, Zelefsky MJ, Mechalakos J, Bilsky MH.

Neurosurg Focus. 2017 Jan;42(1):E6. doi: 10.3171/2016.9.FOCUS16369.

8.

Dynamic contrast-enhanced magnetic resonance imaging of osseous spine metastasis before and 1 hour after high-dose image-guided radiation therapy.

Lis E, Saha A, Peck KK, Zatcky J, Zelefsky MJ, Yamada Y, Holodny AI, Bilsky MH, Karimi S.

Neurosurg Focus. 2017 Jan;42(1):E9. doi: 10.3171/2016.9.FOCUS16378.

9.

A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer.

O'Shaughnessy MJ, McBride SM, Vargas HA, Touijer KA, Morris MJ, Danila DC, Laudone VP, Bochner BH, Sheinfeld J, Dayan ES, Bellomo LP, Sjoberg DD, Heller G, Zelefsky MJ, Eastham JA, Scardino PT, Scher HI.

Urology. 2017 Apr;102:164-172. doi: 10.1016/j.urology.2016.10.044. Epub 2016 Nov 22.

11.

Hip-related toxicity after prostate radiotherapy: Treatment related or coincidental?

Zelefsky MJ, Kollmeier MA, Gorshein E, Pei X, Torres M, McBride S, Happersett L, Cohen GN, Yamada Y.

Radiother Oncol. 2016 Oct;121(1):109-112. doi: 10.1016/j.radonc.2016.08.010. Epub 2016 Oct 15.

12.

American Brachytherapy Society Task Group Report: Combination of brachytherapy and external beam radiation for high-risk prostate cancer.

Spratt DE, Soni PD, McLaughlin PW, Merrick GS, Stock RG, Blasko JC, Zelefsky MJ.

Brachytherapy. 2017 Jan - Feb;16(1):1-12. doi: 10.1016/j.brachy.2016.09.006. Epub 2016 Oct 19. Review.

PMID:
27771243
13.

High-dose hypofractionated radiotherapy is effective and safe for tumors in the head-and-neck.

Teckie S, Lok BH, Rao S, Gutiontov SI, Yamada Y, Berry SL, Zelefsky MJ, Lee NY.

Oral Oncol. 2016 Sep;60:74-80. doi: 10.1016/j.oraloncology.2016.06.016. Epub 2016 Jul 12.

14.

Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage.

Spratt DE, Vargas HA, Zumsteg ZS, Golia Pernicka JS, Osborne JR, Pei X, Zelefsky MJ.

Eur Urol. 2017 Jan;71(1):37-43. doi: 10.1016/j.eururo.2016.07.043. Epub 2016 Aug 11.

PMID:
27523595
15.

Genomic characterization of response to chemoradiation in urothelial bladder cancer.

Desai NB, Scott SN, Zabor EC, Cha EK, Hreiki J, Sfakianos JP, Ramirez R, Bagrodia A, Rosenberg JE, Bajorin DF, Berger MF, Bochner BH, Zelefsky MJ, Kollmeier MA, Ostrovnaya I, Al-Ahmadie HA, Solit DB, Iyer G.

Cancer. 2016 Dec 1;122(23):3715-3723. doi: 10.1002/cncr.30219. Epub 2016 Aug 1.

PMID:
27479538
16.

Localizing sites of disease in patients with rising serum prostate-specific antigen up to 1ng/ml following prostatectomy: How much information can conventional imaging provide?

Vargas HA, Martin-Malburet AG, Takeda T, Corradi RB, Eastham J, Wibmer A, Sala E, Zelefsky MJ, Weber WA, Hricak H.

Urol Oncol. 2016 Nov;34(11):482.e5-482.e10. doi: 10.1016/j.urolonc.2016.05.026. Epub 2016 Jun 23.

17.

Radiation safety of receptive anal intercourse with prostate cancer patients treated with low-dose-rate brachytherapy.

Nasser NJ, Cohen GN, Dauer LT, Zelefsky MJ.

Brachytherapy. 2016 Jul-Aug;15(4):420-5. doi: 10.1016/j.brachy.2016.03.012. Epub 2016 May 12.

18.

Radium-223 outcomes after multiple lines of metastatic castration-resistant prostate cancer therapy in clinical practice: implication of pre-treatment spinal epidural disease.

Spratt DE, Osborne JR, Zumsteg ZS, Rebeiz K, Leeman J, Rivera A, Morris MJ, Zelefsky MJ.

Prostate Cancer Prostatic Dis. 2016 Sep;19(3):271-6. doi: 10.1038/pcan.2016.14. Epub 2016 Apr 26.

PMID:
27112529
19.

Long-term outcome of magnetic resonance spectroscopic image-directed dose escalation for prostate brachytherapy.

King MT, Nasser NJ, Mathur N, Cohen GN, Kollmeier MA, Yuen J, Vargas HA, Pei X, Yamada Y, Zakian KL, Zaider M, Zelefsky MJ.

Brachytherapy. 2016 May-Jun;15(3):266-73. doi: 10.1016/j.brachy.2016.02.003. Epub 2016 Apr 20.

20.

Defining the value framework for prostate brachytherapy using patient-centered outcome metrics and time-driven activity-based costing.

Thaker NG, Pugh TJ, Mahmood U, Choi S, Spinks TE, Martin NE, Sio TT, Kudchadker RJ, Kaplan RS, Kuban DA, Swanson DA, Orio PF, Zelefsky MJ, Cox BW, Potters L, Buchholz TA, Feeley TW, Frank SJ.

Brachytherapy. 2016 May-Jun;15(3):274-82. doi: 10.1016/j.brachy.2016.01.003. Epub 2016 Feb 23.

Supplemental Content

Loading ...
Support Center